Table 2.
Trials using Anti-EGFR mABs as monotherapy for chemoresistant mCRC selected by KRAS status.
| Trial (author) | Phase | KRAS | Protocol | Number enrolled | Results |
HR (95% CI) | P value | |
|---|---|---|---|---|---|---|---|---|
| PFS | OS | |||||||
| — (Amado et al.) [14] | III | WT | Panitumumab BSC |
124 119 |
12.3 wks. 7.3 wks. |
8.1 mos. 7.6 mos. |
PFS: 0.45 (0.34–0.59) OS: 0.99 (0.75–1.29) |
<0.001 NR |
| MUT | Panitumumab BSC |
84 100 |
7.4 wks. 7.3 wks. |
4.9 mos. 4.4 mos. |
PFS: 0.99 (0.73–1.36) OS: 1.02 (0.75–1.39) |
NR NR |
||
BSC: best supportive care, WT: wild type, MUT: mutated, and NR: not reported.